Inventiva (NASDAQ:IVA) Shares Gap Up After Analyst Upgrade

Key Points

• Inventiva's share price rose significantly after Guggenheim raised its price target from $9.00 to $13.00, leading to a gap up at market open from $5.26 to $5.74.
• Piper Sandler initiated coverage on Inventiva, giving it an "overweight" rating and a price target of $26.00, contributing to positive sentiment around the stock.
• Currently, institutional investors own 19.06% of Inventiva's stock, indicating growing interest from larger financial entities.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $9.00 to $13.00. The stock had previously closed at $5.26, but opened at $5.74. Guggenheim currently has a buy rating on the stock. Inventiva shares last traded at $5.66, with a volume of 22,875 shares changing hands.

Separately, Piper Sandler assumed coverage on shares of Inventiva in a report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $14.83.

Institutional Investors Weigh In On Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,558 shares of the company's stock after buying an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.06% of the company's stock.

Inventiva Stock Performance

The firm's 50-day moving average price is $3.90 and its 200 day moving average price is $3.48.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.